Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04446546
Other study ID # 2020PI096
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2014
Est. completion date May 30, 2020

Study information

Verified date June 2020
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Vascular access creation in patients with renal failure requiring long-term hemodialysis can be a challenge when there is no more autologous material or in case of infection, in a population undergoing long term dialysis with a longer life-expectancy. Many types of grafts have been used, with its advantages and drawbacks, such as prosthetic grafts (PTFE). Over the past decade, surgeons have used cold stored venous allografts as a biological conduit for hemodialysis, with the idea of avoiding most of major complications including a lower incidence of infection and steal syndrome, with patencies at least equivalent to PTFE. There is only a few data in the litterature, but many surgical teams use it when there is no autologous material or in case of infection.

The aim of the study is to give the primary patency of vascular access with this technique, and to assess its long term outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date May 30, 2020
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- End stage renal failure patient requiring hemodialysis

- With the placement of a venous allograft for a hemodialysis approach

- Who underwent a surgery between January 1, 2014 and December 31, 2018 in a vascular surgery department participating in our study

Exclusion Criteria:

- Patient <18 years old, or under guardianship / curatorship

- Patient objecting to the use of his personal data in the context of research

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Vascular access by pass using a cold stored venous allograft
Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft

Locations

Country Name City State
France Departement of Vascular Surgery Nancy University Hospital Nancy Lorraine

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

References & Publications (5)

Berardinelli L. Grafts and graft materials as vascular substitutes for haemodialysis access construction. Eur J Vasc Endovasc Surg. 2006 Aug;32(2):203-11. Epub 2006 Feb 20. Review. — View Citation

Heintjes RJ, Eikelboom BC, Steijling JJ, van Reedt Dortland RW, van der Heijden FH, Bastini M, van der Graaf Y, Blankestijn PJ, Vos J. The results of denatured homologous vein grafts as conduits for secondary haemodialysis access surgery. Eur J Vasc Endovasc Surg. 1995 Jan;9(1):58-63. — View Citation

Nedved K, Suchý T, Hálová J, Malický M, Gorun P, Vitvar P. Allogenous vein graft as vascular access for hemodialysis--lost battle? J Vasc Access. 2012 Jul-Sep;13(3):366-73. doi: 10.5301/jva.5000062. — View Citation

Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, Haage P, Hamilton G, Hedin U, Kamper L, Lazarides MK, Lindsey B, Mestres G, Pegoraro M, Roy J, Setacci C, Shemesh D, Tordoir JHM, van Loon M, Esvs Guidelines Committee, Kolh P, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Lindholt J, Naylor R, Vega de Ceniga M, Vermassen F, Verzini F, Esvs Guidelines Reviewers, Mohaupt M, Ricco JB, Roca-Tey R. Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018 Jun;55(6):757-818. doi: 10.1016/j.ejvs.2018.02.001. Epub 2018 May 2. — View Citation

Schneider M, Barrou B, Cluzel P, Hamani A, Bitker MO, Richard F. [Value of preserved saphenous vein graft for the creation of access ports in hemodialyzed patients: report of 309 cases]. Prog Urol. 2003 Sep;13(4):585-91. French. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Early and late complications (in days) The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) 30 days
Other Early and late complications (in days) The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) 90 days
Other Early and late complications (in days) The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) 6 months
Other Early and late complications (in days) The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) 1 year
Other Early and late complications (in days) The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) 2 years
Other Early and late complications (in days) The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) 3 years
Other Incidence of the socio-demographic and clinical characteristics of the patients on secondary patency Compare the duration of secondary patency according to the socio-demographic and clinical characteristics of the patients 3 years
Primary Intervention free vascular access survival (in days) The interval in days between the vascular access creation and the first successful re intervention (primary patency) 30 days
Primary Intervention free vascular access survival (in days) The interval in days between the vascular access creation and the first successful re intervention (primary patency) 6 months
Primary Intervention free vascular access survival (in days) The interval in days between the vascular access creation and the first successful re intervention (primary patency) 1 year
Primary Intervention free vascular access survival (in days) The interval in days between the vascular access creation and the first successful re intervention (primary patency) 2 years
Primary Intervention free vascular access survival (in days) The interval in days between the vascular access creation and the first successful re intervention (primary patency) 3 years
Secondary Thrombosis free vascular access survival (in days) The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) 30 days
Secondary Thrombosis free vascular access survival (in days) The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) 90 days
Secondary Thrombosis free vascular access survival (in days) The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) 6 months
Secondary Thrombosis free vascular access survival (in days) The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) 1 year
Secondary Thrombosis free vascular access survival (in days) The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) 2 years
Secondary Thrombosis free vascular access survival (in days) The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) 3 years
Secondary Abandonment of the vascular access (in days) The interval in days between the vascular access creation and its abandonment (secondary patency) 30 days
Secondary Abandonment of the vascular access (in days) The interval in days between the vascular access creation and its abandonment (secondary patency) 90 days
Secondary Abandonment of the vascular access (in days) The interval in days between the vascular access creation and its abandonment (secondary patency) 6 months
Secondary Abandonment of the vascular access (in days) The interval in days between the vascular access creation and its abandonment (secondary patency) 1 year
Secondary Abandonment of the vascular access (in days) The interval in days between the vascular access creation and its abandonment (secondary patency) 2 years
Secondary Abandonment of the vascular access (in days) The interval in days between the vascular access creation and its abandonment (secondary patency) 3 years
See also
  Status Clinical Trial Phase
Completed NCT04103177 - Physical Activity in Haemodialysis Patients: a Feasibility Study N/A
Completed NCT01561118 - DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis N/A
Withdrawn NCT03645720 - The Prognosis of Graft Using Plastic Cannula in Hemodialysis N/A
Active, not recruiting NCT02598635 - Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis Phase 4
Terminated NCT01643733 - Study on Fistuloplasty Using Flow Measurement Guidance N/A
Not yet recruiting NCT03169400 - Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) N/A
Completed NCT02439697 - A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients N/A
Completed NCT02063490 - Nurse-led Intervention to Improve Phosphate Binder Adherence N/A
Completed NCT04106310 - Theranova vs High-flux HD Comparison N/A
Recruiting NCT06056102 - CAR-T Cell Therapy for Desensitization in Kidney Transplantation Phase 1
Completed NCT04698512 - MAgicTouchâ„¢ Intervention Leap for Dialysis Access (MATILDA) Trial
Completed NCT02819011 - OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO Phase 2
Completed NCT02484118 - Hemodialysis Blood Flow and Urea Clearance N/A
Enrolling by invitation NCT01641757 - Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy, Phase 2
Completed NCT03172039 - Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit N/A
Completed NCT03897231 - Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis
Withdrawn NCT03145662 - High Pressure Balloon vs Cutting Balloon N/A
Completed NCT02621918 - The Effects of Exercise in End-stage Renal Disease Patients Undergoing Hemodialysis N/A
Completed NCT01356615 - Low Molecular Weight Heparin for Hemodialysis Anticoagulation N/A
Terminated NCT01033357 - Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access N/A